Last edition
News about "Eli Lilly"
AltrixBio Raises USD 5 Million Series A Financing and Appoints David Pass as CEO
Dr David Pass, a veteran of the pharma, biotech, and medical device sectors with a track record of scaling programs to over USD 1 billion in sales, succeeds AltrixBio Co-Founder and CEO Nancy Briefs, who led the company from inception and will now serve as Executive Chair.
Eli Lilly | 18/09/2025 | By Dineshwori
Orforglipron by Lily Shows Significant Weight Loss and Cardiometabolic Gains in ATTAIN-1 Results
Orforglipron by Eli Lily demonstrated significant improvements across key cardiometabolic risk factors, supporting its potential as a treatment option for millions living with obesity.
Eli Lilly | 18/09/2025 | By Dineshwori
Lilly Drug Jaypirca Delivers Positive Results in CLL Patients
Lilly’s Jaypirca showed a strong Progression-Free Survival (PFS) benefit in front-line CLL, with data from BRUIN studies set to support global label expansion filings.
Eli Lilly | 10/09/2025 | By Dineshwori
FDA tightens import controls on obesity drug ingredients amid safety concerns
The Food and Drug Administration (FDA) in the USA has intensified its scrutiny of imports containing GLP-1 drug ingredients, widely used in treatments for weight loss and diabetes, following increasing concerns over safety and quality.
Eli Lilly | 06/09/2025 | By Darshana | 195
Eli Lilly Announces Retirement of Anne White, Begins Search for Next Neuroscience Chief
Eli Lilly has announced that Anne White, Executive Vice President and President, Lilly Neuroscience, will retire from the company on December 31, 2025, after three decades of service.
Eli Lilly | 21/08/2025 | By Dineshwori
Superluminal and Eli Lilly Partner on Next-Gen Cardiometabolic and Obesity Treatments
Superluminal Medicines has announced a collaboration with Eli Lilly and Company to advance small molecule therapeutics for cardiometabolic diseases and obesity.
Eli Lilly | 16/08/2025 | By Dineshwori
Eli Lilly has voiced opposition to proposed tariffs on pharmaceutical products, cautioning that such measures could increase costs, limit patient access, and weaken US leadership in biopharmaceutical innovation.
Eli Lilly | 16/08/2025 | By Dineshwori
Merck, BMS, Pfizer to Be Hit Hard by Looming Patent Cliff: Report Warns
Major pharmaceutical players, including Merck, Bristol Myers Squibb (BMS), Johnson and Johnson, Pfizer, and Novartis, are expected to experience significant revenue losses as several of their blockbuster drugs approach patent expirations, according to a new report by Research and Markets.
Eli Lilly | 28/07/2025 | By Dineshwori | 174
Lilly Acquires New Injectable Medicine Manufacturing Facility from Nexus
Eli Lilly has signed a definitive agreement with Nexus Pharmaceuticals wherein Lilly will be acquiring a manufacturing facility from Nexus.
Eli Lilly | 23/04/2024 | By Aishwarya | 371
Eli Lilly Selects ABEC for Single-Use Biopharma Manufacturing Facility
Eli Lilly Selects ABEC for Single-Use Biopharma Manufacturing Facility
Eli Lilly | 13/07/2023 | By Sudeep Soparkar | 718
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy